FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA Compliance for Peptide Therapy and BPC 157 Holt Law 503A Vs. 503B Compounding Pharmacies: Similarities & Differences 503A vs. 503B Compounding Pharmacies The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York